<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006273</url>
  </required_header>
  <id_info>
    <org_study_id>NCRR-M01RR00750-9040</org_study_id>
    <secondary_id>IU-9509-20</secondary_id>
    <nct_id>NCT00006273</nct_id>
  </id_info>
  <brief_title>Study of Total Energy Expenditure in Infants and Children With Moderate to Severe Cystic Fibrosis</brief_title>
  <official_title>Study of Total Energy Expenditure in Infants and Children With Moderate to Severe Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Indiana University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Center for Research Resources (NCRR)</source>
  <brief_summary>
    <textblock>
      OBJECTIVES: I. Compare the resting energy expenditure using respiratory calorimetry in&#xD;
      infants and children with moderate to severe cystic fibrosis versus age matched healthy&#xD;
      controls.&#xD;
&#xD;
      II. Determine the total energy expenditure and energy spent on physical activity using the&#xD;
      doubly labeled water method in these patient populations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: Patients and healthy controls receive an oral dose of doubly labeled water&#xD;
      following initial urine collection on day 1. Patients undergo additional urine collection at&#xD;
      4-6 hours following doubly labeled water consumption and then daily for 7 days.&#xD;
&#xD;
      Additionally, at the beginning of the study, patients and healthy controls undergo&#xD;
      respiratory calorimetry over approximately 45 minutes at rest, starting approximately 2-3&#xD;
      hours after the last meal consumption and last use of aerosol bronchodilators (if required).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 1996</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Natural History</observational_model>
  </study_design_info>
  <enrollment>60</enrollment>
  <condition>Cystic Fibrosis</condition>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        --Disease Characteristics--&#xD;
&#xD;
          -  Diagnosis of cystic fibrosis (CF) by two positive sweat tests No exacerbations of&#xD;
             present condition within past 2 months FEV1 less than 50% of predicted No other&#xD;
             uncorrected lung disease No requirement for supplemental oxygen&#xD;
&#xD;
        OR&#xD;
&#xD;
          -  Healthy (control group) Age matched to CF patients No preexisting lung disease&#xD;
             Clinically well No hospitalizations within past 6 months&#xD;
&#xD;
        --Prior/Concurrent Therapy--&#xD;
&#xD;
          -  Concurrent pancreatic enzyme supplementation for CF required Clinically stable on&#xD;
             current medications (CF patients)&#xD;
&#xD;
        --Patient Characteristics--&#xD;
&#xD;
          -  Age: Birth to 12 months 6 to 10 years&#xD;
&#xD;
          -  Cardiovascular: No major cardiovascular problems (CF patients) No preexisting heart&#xD;
             disease (control group)&#xD;
&#xD;
          -  Pulmonary: See Disease Characteristics&#xD;
&#xD;
          -  Other: No chromosomal abnormalities (CF patients) No acute infection (CF patients) No&#xD;
             diabetes mellitus (both groups)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>0 Years</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catherine A. Leitch</last_name>
    <role>Study Chair</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-5167</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2003</verification_date>
  <study_first_submitted>September 11, 2000</study_first_submitted>
  <study_first_submitted_qc>September 11, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2000</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>cardiovascular and respiratory diseases</keyword>
  <keyword>cystic fibrosis</keyword>
  <keyword>genetic diseases and dysmorphic syndromes</keyword>
  <keyword>rare disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

